ArticleHemodialysis international. International Symposium on Home Hemodialysis2026
Serum Visfatin Level and Cardiac Valve Calcifcation in Hemodialysis Patients.
Article in Hemodialysis international. International Symposium on Home Hemodialysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Visfatin Level and Cardiac Valve Calcifcation in Hemodialysis Patients.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac valve calcification is a serious complication in patients with cardiovascular disease. This study investigated the relationship between visfatin levels and cardiac valve calcification in individuals undergoing hemodialysis.
methodsWe conducted a cross-sectional study at Beijing Luhe Hospital of Capital Medical University, enrolling 339 maintenance hemodialysis patients between June 2023 and May 2024. We collected baseline data including sex, age, underlying diseases, electrolyte levels, and parathyroid hormone levels. Patients were categorized into cardiac valve calcification and non-cardiac valve calcification groups based on echocardiogram findings; we analyzed associations between valve calcification and clinical data.
resultsOf the 339 hemodialysis patients, 186 (55.8%) were male, with an average age of 66.1 ± 12.5 years and a mean dialysis duration of 58.7 ± 45.3 months. Cardiac valve calcification was present in 36.7% of patients. Compared to the non-cardiac valve calcification group, patients with cardiac valve calcification were significantly older, had longer dialysis durations, a higher prevalence of coronary heart disease, longer histories of hypertension, elevated intact parathyroid hormone levels, and increased visfatin levels (p < 0.05). Logistic regression analysis identified advanced age, prolonged dialysis duration, an extended hypertension history, and elevated serum visfatin as factors associated with valve calcification.
conclusionOur findings indicate that cardiac valve calcification is significantly linked to advanced age and higher visfatin concentrations in hemodialysis patients. Calcium and phosphate levels did not show significant group differences in this study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.